AOD-9604 at a Glance

• AOD-9604 is a 16-residue synthetic peptide corresponding to the C-terminal region of human growth hormone, described in the originating literature as the hGH 177–191 lipolytic domain with an added N-terminal tyrosine. It came out of an Australian programme: Ng and colleagues at Monash University, commercialised by Metabolic Pharmaceuticals.
• The central claim was dissociation: that the fragment reproduces growth hormone’s lipolytic action without its effects on IGF-1 and insulin sensitivity. The rodent data genuinely support that dissociation.
• Beta-3 adrenergic receptor involvement is contested, and the primary literature settles it against a direct role. In β3-AR knockout mice, chronic AOD9604 failed to reduce body weight, yet acute dosing still increased energy expenditure and fat oxidation, leading the investigators to conclude the lipolytic action is not mediated directly through the β3-AR.
• The human weight-loss evidence is weak, and this is the most important fact in the dossier. Australia’s Therapeutic Goods Administration recorded in a 2015 scheduling decision that the obesity programme “was discontinued in 2007 as the clinical trials did not show a meaningful weight loss”.
• The compound was later repositioned toward osteoarthritis and cartilage where the preclinical work is a single rabbit intra-articular study.
• WADA classifies it as a non-approved substance under S0 prohibited at all times, and the TGA placed it in Schedule 4 and Appendix D effective 1 June 2015. It has no FDA drug approval and the widely repeated “FDA GRAS” claim concerns a food-ingredient determination. All material discussed here is research-use-only.

What Is AOD-9604?

AOD-9604 is catalogued in PubChem as CID 71300630 with the molecular formula C₇₈H₁₂₃N₂₃O₂₃S₂ and a molecular weight of approximately 1.8 kDa. The name follows its origin: AOD for “anti-obesity drug”, 9604 for the compound number in the sponsor’s series. Structurally it is a hexadecapeptide, 16 residues, corresponding to the C-terminal tail of the 191-residue human growth hormone molecule, and the originating literature describes it as a synthetic analogue of hGH’s lipolytic domain comprising residues 177–191 with a tyrosine added at the N-terminus.

One chemical detail is worth noting because it affects handling and analysis. The fragment contains two cysteine residues and the catalogued formula carries two hydrogens fewer than the corresponding fully reduced linear hexadecapeptide, C₇₈H₁₂₅N₂₃O₂₃S₂, catalogued separately in PubChem, exactly what an intramolecular disulfide bond produces. A cystine-containing peptide is redox-sensitive: it can be reduced, scrambled or dimerised, none of it visible, and all of it something an analytical certificate should address.

The name “AOD-9604” is also used loosely in the market as a synonym for hGH fragment 176–191. Whether the two are chemically identical or merely closely related is exactly what a lot-matched certificate exists to answer, and a supplier treating the names as interchangeable without analytical support has not answered it.

How Does AOD-9604 Work?

The Lipolytic Domain Hypothesis

Growth hormone has a well-established lipolytic action on adipose tissue; it also raises IGF-1, promotes tissue growth and impairs insulin sensitivity. The hypothesis behind AOD-9604 was structural: that these activities are carried by different domains of the hGH molecule, so a fragment could be synthesised retaining the fat-metabolism activity while leaving the growth-promoting and glycaemic activities behind. A related domain fragment, AOD9401 was characterised for its actions on lipid metabolism in Zucker fatty rats before the 9604 series was advanced.

Separating Lipolysis from the IGF-1 and Insulin Effects

The dissociation claim is the part of the dossier best supported by the primary literature. Ng and colleagues (2000), in Hormone Research, studied AOD9604 in obese Zucker rats: adipose tissue from treated animals showed increased lipolytic activity, and oral dosing at 500 µg/kg for 19 days reduced weight gain by more than 50%. Critically, chronic treatment showed no adverse effect on insulin sensitivity as measured by euglycaemic clamp, in contrast to intact hGH. The authors concluded the compound could potentially become an orally usable and safe agent for obesity.

That is a real result and it should be credited: the fragment behaved differently from the parent hormone on the metabolic axis that limits growth hormone’s usefulness. Whether that difference translated into a clinically meaningful effect in people is a separate question, answered below, and answered unfavourably.

The Beta-3 Adrenergic Receptor Question

The β3-adrenergic receptor is the mechanism most frequently attributed to AOD-9604 in secondary writing, and the primary literature is far less supportive than that attribution implies. Heffernan and colleagues (2001), in Endocrinology, examined hGH and AOD9604 in obese mice and in β3-AR knockout mice. In obese mice, 14 days of chronic intraperitoneal administration of either compound reduced body weight and body fat and restored suppressed β3-AR expression to levels comparable with lean controls. That is the finding that generated the β3 story.

The knockout experiment inverted it. In β3-AR knockout mice, chronic treatment failed to produce weight reduction while acute AOD9604 exposure still increased energy expenditure and fat oxidation. The authors’ conclusion was explicit: the lipolytic actions of both hGH and AOD9604 are not mediated directly through the β3-AR.

The honest reading is layered. The β3-AR appears necessary for the chronic weight phenotype in that model, and AOD9604 increases β3-AR expression but the acute metabolic effects survive removal of the receptor, so it is not the direct target. Any claim that AOD-9604 “works via the β3 receptor” is contradicted by the paper usually cited for it.

What the Mechanism Is Not

Three negatives are worth stating plainly, because they are frequently elided. AOD-9604 is not a growth hormone secretagogue it does not act on the GHRH or ghrelin receptor and does not stimulate endogenous GH release, which is precisely the distinction from tesamorelin and the GHRH analogue class. It does not raise IGF-1 which is the point of the design rather than an omission from it. And no specific receptor has been established as its molecular target the GH–IGF-1 axis is well described, the receptor-level pharmacology of its fragments is not.

Research Evidence

Rodent Lipolysis and Obese Mouse Studies

The rodent dataset is the strongest part of the evidence base, and it is consistent across models. In obese Zucker rats, oral AOD9604 at 500 µg/kg for 19 days reduced weight gain by more than 50%, with increased adipose lipolytic activity and no clamp-detected loss of insulin sensitivity (PMID 11146367). In obese mice, Heffernan and colleagues (2001), in the International Journal of Obesity, reported increased fat oxidation and weight loss following chronic treatment with either human growth hormone or a modified C-terminal fragment, and the Endocrinology study above reported reduced body weight and body fat after 14 days of chronic intraperitoneal administration.

Taken together: reproducible reductions in fat mass and weight gain across two rodent species, by two routes, with a coherent effect on fat oxidation and no evident glycaemic penalty. That is a respectable preclinical package, and why the compound advanced to human study.

The Human Trials, and the Phase 2b Outcome

This is where the dossier turns, and it is the section most often omitted. Begin with a structural observation about the literature itself. A search of the indexed biomedical literature for AOD9604 returns a small body of work, the rodent studies above, a rabbit osteoarthritis study, two analytical-chemistry papers and a handful of recent reviews. No human clinical trial of AOD9604 appears in the indexed literature. Safety and tolerability data in humans were published in a non-indexed journal (Stier, Vos and Kenley, Journal of Endocrinology and Metabolism, 2013;3(1-2):7–15), and the obesity programme’s efficacy results were communicated principally through sponsor announcements and conference presentations. That is itself informative: a compound with a positive pivotal outcome is published.

And the outcome was negative. The clearest statement of it in the public record comes not from the sponsor but from a regulator. In its final scheduling decision of March 2015 the Australian Therapeutic Goods Administration’s delegate, setting out reasons for placing AOD-9604 in Schedule 4, recorded that the substance “was initially developed as an anti-obesity drug, but the obesity program was discontinued in 2007 as the clinical trials did not show a meaningful weight loss” (TGA final scheduling decisions, March 2015). The same document cites limited data on the safety of intravenous and subcutaneous use and on long-term oral use.

That is a regulator’s own account of the phase 2b programme, and it should be treated as definitive. The human weight-loss claim for AOD-9604 is not supported; rodent fat-mass reductions did not translate. This is a common outcome in obesity pharmacology and not a scandal, but it is the fact any accurate description of the compound has to carry. A 2026 review of approved and unapproved peptides in sports medicine makes the general version of the point: many unapproved peptides show favourable outcomes in animal models, but rigorous human safety data are scarce and social-media amplification inflates perceived efficacy.

Repositioning Toward Osteoarthritis and Cartilage

After the obesity programme closed, development interest shifted to joint and cartilage indications. The principal preclinical citation is Kwon and Park (2015), who examined intra-articular injection of AOD9604 with or without hyaluronic acid in a rabbit osteoarthritis model and reported that the combination was more effective than either agent alone in reducing cartilage degeneration and lameness.

Two caveats: this is a single small-animal study with a local route of administration rather than a systemic metabolic study, and the comparator design entangles the AOD9604 contribution with hyaluronic acid’s own established intra-articular effect. A 2026 orthopaedic review lists AOD-9604 among peptides discussed in that setting while noting a current lack of clinical trials supporting the proposed mechanisms in humans.

Detection, Metabolism and Stability

The analytical literature on AOD-9604 is small but unusually useful, because it was generated for anti-doping purposes and speaks directly to handling. Cox and colleagues (2015), in Drug Testing and Analysis, validated urinary detection to a limit of 50 pg/mL and identified six potential metabolites one reported as significantly more stable than the others or the parent compound. A 2026 harmonised workflow for peptidic and non-peptidic doping agents in blood matrices reported that AOD9604 was extensively degraded after one week in serum and plasma at higher temperatures while remaining stable in dried blood samples (PMID 42328738), a laboratory-relevant stability datum rather than a doping curiosity.

What Remains Unknown

No molecular target is established after two decades the compound has no identified receptor, and the β3-AR hypothesis is contradicted by the knockout data. Human efficacy is unestablished for any indication: obesity was tested and the programme discontinued, and cartilage has not been tested in indexed human trials. Long-term human safety is uncharacterised as the TGA delegate said explicitly in 2015. And the disulfide question is unaddressed in the public literature for a cystine-containing peptide, the relative activity of reduced, oxidised, scrambled and dimeric species is a first-order question that is not answered.

Comparison: AOD-9604, Tesamorelin and 5-Amino-1MQ

These three appear together in metabolic research catalogues and occupy entirely different positions on both the mechanism and the evidence axes. The contrast with tesamorelin is the instructive one.

Tesamorelin is the comparison that matters, because it is what a positive GH-axis result looks like. A 44-residue GHRH analogue, it was tested in randomised trials in HIV-associated lipodystrophy, Falutz and colleagues reported reduced visceral adipose tissue in the New England Journal of Medicine in 2007, and holds an FDA approval for that indication, though its path was not uniformly smooth, the European marketing authorisation application for Egrifta was withdrawn by the applicant. Critically, it raises IGF-1 as an on-target consequence of stimulating endogenous GH, exactly the trade-off the fragment strategy was meant to resolve. Tesamorelin is catalogued separately because the two are not interchangeable in any respect.

5-Amino-1MQ is not a peptide at all but a small-molecule inhibitor of nicotinamide N-methyltransferase, reported to reduce fat mass in diet-induced obese mice without altering food intake (PMID 29155147), with no human data. Catalogues list 5-Amino-1MQ as a distinct research compound, and its handling differs because it is a charged salt rather than a lyophilised peptide.

Handling a 16-Amino-Acid Fragment

AOD-9604 research material is supplied lyophilised and handled as a genuine peptide, with two specific liabilities. The disulfide is the distinguishing one: a cystine-containing peptide is redox-sensitive, and reducing agents, trace metals and prolonged exposure to air in solution can reduce, scramble or dimerise it, none of it visible. Avoid thiol-containing buffers unless the experiment requires them, keep solutions free of trace copper and iron, and treat any analytical method that cannot distinguish reduced from oxidised species as incomplete. Aqueous stability is limited: the doping-analysis literature reports extensive degradation in serum and plasma within a week at elevated temperature. That is a biological matrix rather than a clean buffer, but it sets expectations, reconstituted peptide is a perishable reagent, not a stock solution.

Practical workflow for a lyophilised peptide:

• Bring the vial to room temperature before opening to avoid condensing atmospheric moisture onto cold glass, then disinfect the septum with 70% isopropyl alcohol.
• Add diluent slowly down the inner wall not onto the cake, which shears and foams peptide at the liquid interface.
• Swirl gently; never shake or vortex. Foaming is a visible sign of the aggregation that agitation causes.
• Aliquot at the point of reconstitution recording date, diluent and nominal concentration. Repeated freeze–thaw cycling of a disulfide-containing peptide reliably loses defined content.
• Store cold and protected from light and treat discoloration, particulate or incomplete dissolution as a stability signal rather than a cosmetic one.

For multi-entry aqueous preparations, a bacteriostatic water meeting Bacteriostatic Water for Injection, USP, of the kind listed beside research compounds at NextGenPeps, is what most laboratory protocols specify, because its benzyl alcohol preservative suppresses microbial growth between entries. Two caveats travel with it: benzyl alcohol is not inert toward peptides and absorbs in the ultraviolet, so single-entry analytical preparations are better served by unpreserved sterile water; and it is contraindicated in neonatal use.

Is AOD-9604 FDA Approved?

No. AOD-9604 holds no drug approval from the FDA, the EMA or any comparable authority, for any indication in any species: no marketing authorisation, no approved labelling, no approved route of administration. Three regulatory threads are frequently confused with approval, and each deserves separating.

The GRAS claim. AOD-9604 is often described as having “FDA GRAS status”. Generally Recognised As Safe is a food-ingredient framework, entirely separate from drug approval, and it says nothing about safety or efficacy as a pharmacological agent or about injectable research material. The framework also distinguishes two very different things: a notified GRAS conclusion, submitted to the agency and receiving a response recorded in the public GRAS Notice Inventory, and a self-affirmed determination, commissioned by the sponsor and receiving no agency review at all. A GRAS claim that cannot be matched to an inventory entry is a self-affirmed one. In neither case is it drug approval, and citing it as though it were is the single most common misstatement about this compound.

The compounding record. AOD-9604 appears on the FDA’s page covering bulk drug substances for use in compounding under section 503A, in the section listing substances nominated but withdrawn not among those the agency evaluated and placed in the Category 2 list of substances that may present significant safety risks (FDA, certain bulk drug substances). A withdrawn nomination was never adjudicated: neither approval nor prohibition.

The Australian and anti-doping position. This is the most concrete regulatory record. The TGA placed AOD-9604 in Schedule 4 and Appendix D, Item 5 effective 1 June 2015 citing limited safety data for intravenous and subcutaneous use and for long-term oral use, the discontinued obesity programme, evidence of organised-crime involvement in supply, and the marketing of such substances as supposedly safe alternatives to anabolic steroids. Separately, the World Anti-Doping Agency’s statement on AOD-9604 records that it is “still under pre-clinical and clinical development and has not been approved for therapeutic use by any government health authority in the world”, placing it in category S0, non-approved substances, prohibited at all times in sport. Validated urinary detection methods exist, so the compound is detectable.

Material sold for laboratory work is research-use-only and supplier documentation carries the entire evidentiary burden.

Where to Source Research-Grade AOD-9604

The sourcing case for this compound is unusually well documented, because AOD-9604 is one of very few research peptides to have been the subject of a published forensic analysis. Vanhee and colleagues (2014), in Drug Testing and Analysis, reported the identification and characterisation of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities, in a case report on AOD9604. Unlabelled and mislabelled preparations of this specific peptide are documented, not hypothetical. A defensible purchase record contains:

• A lot-matched certificate of analysis tied to the specific lot shipped rather than a representative batch.
• Mass spectrometric confirmation consistent with the expected ~1.8 kDa, ideally distinguishing the oxidised (disulfide-closed) form from the reduced linear form a two-dalton difference a competent method resolves and an incompetent one does not.
• Sequence confirmation and explicit statement of whether the material is AOD-9604 as characterised in the primary literature or the related hGH fragment 176–191, with analytical support for whichever is claimed.
• HPLC or UPLC purity from a named third-party laboratory with a stated method, mobile phase, gradient, detection wavelength, and a test date.
• Net peptide content reported separately from chromatographic purity, because counter-ion and residual water can be a substantial fraction of vial mass.
• Residual trifluoroacetate and solvent data TFA being a routine residue of reverse-phase purification with biological activity of its own in cell-based assays.
• Endotoxin data where the work requires it, and explicit research-use-only labelling with no protocol, dosing guidance, human-use framing or therapeutic claim in the listing.

Red flags here are specific. A listing that claims FDA approval or presents GRAS status as drug approval, has made a factual error about the regulatory record. A listing that asserts clinically demonstrated weight loss contradicts the regulator’s own account of the discontinued obesity programme. A listing stating a β3-adrenergic mechanism as settled fact is repeating a claim the cited paper disproves. A certificate with no named laboratory, lot reference or test date is decoration rather than evidence, and any listing supplying a human protocol or injection schedule has left the research-use-only frame entirely.

A catalogue that lists AOD-9604 as a research compound can be assessed against exactly these criteria: lot-matched third-party analysis, mass confirmation resolving the disulfide state, sequence confirmation, a stated HPLC method, net peptide content reported separately, and research-use-only labelling with no protocol content attached.

Frequently Asked Questions

What exactly is AOD-9604?

A 16-residue synthetic peptide corresponding to the C-terminal region of human growth hormone, described in the originating literature as the hGH 177–191 lipolytic domain with a tyrosine added at the N-terminus. Its molecular weight is approximately 1.8 kDa, and the catalogued formula is consistent with an intramolecular disulfide bond between its two cysteines.

Does AOD-9604 actually cause weight loss in humans?

The human evidence does not support that claim. Australia’s Therapeutic Goods Administration recorded in its March 2015 scheduling decision that the obesity programme was discontinued in 2007 because the clinical trials did not show a meaningful weight loss, and no human clinical trial of the compound appears in the indexed biomedical literature. The rodent fat-mass findings are real; they did not translate.

Does it work through the beta-3 adrenergic receptor?

The primary literature says no, not directly. In obese mice AOD9604 restored suppressed β3-AR expression toward lean levels, but in β3-AR knockout mice chronic treatment failed to reduce body weight while acute dosing still increased energy expenditure and fat oxidation, leading the investigators to conclude that the lipolytic actions of both hGH and AOD9604 are not mediated directly through the β3-AR. No molecular target has been established.

Does AOD-9604 raise IGF-1 like growth hormone?

Not according to the design rationale or the rodent data. The premise of the fragment was to separate growth hormone’s lipolytic action from its effects on IGF-1 and insulin sensitivity, and in obese Zucker rats chronic treatment showed no adverse effect on insulin sensitivity by euglycaemic clamp, unlike intact hGH. This dissociation is the best-supported part of the dossier.

How does it differ from tesamorelin?

Fundamentally. Tesamorelin is a 44-residue GHRH analogue acting on the GHRH receptor to stimulate endogenous growth hormone release, and consequently raises IGF-1; it has positive randomised trials and an FDA approval for HIV-associated lipodystrophy. AOD-9604 is a fragment of growth hormone itself, does not stimulate GH release, does not raise IGF-1, has no established receptor and has no approval anywhere.

What doses have been used in research?

Published rodent work used oral dosing at 500 µg/kg for 19 days in obese Zucker rats, and 14 days of chronic intraperitoneal administration in obese mice; the rabbit osteoarthritis study used intra-articular injection. These figures are reported as they appear in the cited animal literature, in the named model with the named route, and do not translate to other species, routes or contexts.

Is AOD-9604 banned in sport?

Yes. WADA’s public statement records that the substance has not been approved for therapeutic use by any government health authority and places it in category S0, non-approved substances, prohibited at all times. Validated urinary detection methods with a reported limit of 50 pg/mL have been published, so it is detectable.

The Bottom Line

AOD-9604 is a well-characterised molecule attached to an elegant hypothesis and a disappointing clinical result, and an accurate account has to hold all three together.

What is real: the dissociation premise worked in animals. A 16-residue C-terminal fragment of growth hormone increased adipose lipolytic activity and reduced weight gain in obese Zucker rats and obese mice, by oral and intraperitoneal routes, without the loss of insulin sensitivity that limits intact growth hormone. That is a legitimate structural result and the reason the compound has a literature at all.

What is not real: the human weight-loss claim. The obesity programme was discontinued in 2007 because the clinical trials did not show a meaningful weight loss, the regulator’s own words, not a critic’s, and no indexed human trial exists. The β3-adrenergic mechanism so often stated as fact is contradicted by the knockout experiment in the paper most often cited for it, and no molecular target has been identified in twenty-five years. The cartilage repositioning rests on one rabbit study in which the compound’s contribution is entangled with hyaluronic acid. And “FDA GRAS” is a food-ingredient framework with nothing to say about a peptide in a research vial.

Read correctly, AOD-9604 is a useful case study in translational failure and a legitimate tool for interrogating growth hormone domain structure and adipocyte lipid metabolism in animal models. Read as marketing usually reads it, it is a fat-loss peptide with clinical support, the one thing the evidence clearly establishes it is not.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

AOD-9604 and all other compounds discussed in this article are intended for laboratory research use only and are not for human or veterinary use. AOD-9604 is not approved by the U.S. Food and Drug Administration or any comparable regulatory authority for the diagnosis, treatment, cure or prevention of any disease, in any species. Generally Recognised As Safe status, where claimed, is a food-ingredient framework and is not drug approval; a withdrawn nomination to a compounding bulk drug substances list is neither approval nor prohibition.

Nothing here is medical, veterinary or pharmaceutical advice, and nothing in it constitutes a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind. Doses quoted from the literature are reported in the terms the original investigators used, micrograms or milligrams per kilogram in the named animal model with the named route and duration, and are not recommendations, conversions or equivalents for any other species or route. Where an approved product exists for a comparator compound, its label facts are reported solely as regulatory record.

Bacteriostatic Water for Injection, USP contains benzyl alcohol and is contraindicated in neonates. Readers with clinical questions should consult a qualified healthcare professional, and are responsible for compliance with all applicable laws, institutional review and animal ethics requirements, anti-doping regulations and biosafety rules.

Stay updated, free articles. Join our Telegram channel

Join